Legend Biotech appoints Ingrid Zhang as CEO

Ingrid Zhang has been appointed Chief Executive Officer of Legend Biotech after a board-led search, Legend said on September 15. The company’s announcement says Zhang will guide the pipeline and long-term growth strategy; Reuters reported that the company selected the Novartis veteran as its new CEO.\n\nThe board’s brief is specific: advance Legend’s pipeline, expand its impact, continue developing CARVYKTI and deliver sustained growth. The announcement does not set out a predecessor or an effective date, so the useful signal is the mandate rather than a staged handover.\n\nA pipeline-led mandate\n\nZhang arrives with experience in global biopharma and a remit that connects product development with commercial scale. For a company built around cell therapy, that combination matters: the CEO role sits at the junction of scientific execution, patient impact and the discipline required to grow a platform. The board said its search concluded that Zhang was the right leader for the next phase.\n\nHer appointment follows a run of healthcare leadership changes that have put operating depth and governance in the same frame, including Health Catalyst’s move to Simeon Kohl.